genedrive plc engages in the design, development, and manufacture of molecular diagnostics testing equipment for use in genotyping, pathogen detection, infectious disease detection, and other clinical indications. The company provides Genedrive system, rapid nucleic acid thermocycler and fluorescence signal detection system for target discrimination used for qualitative in vitro molecular diagnostic tests; and Genedrive CYP2C19 ID Kit, a certified test for identification of individuals unlikely to respond to the commonly prescribed antiplatelet drug Clopidogrel. It also offers Genedrive MT-RNR1-ID Kit, a rapid genetic test in an emergency neonatal care setting; and tests for the detection of Antibiotic Induced Hearing Loss in neonates, confirmation of HCV infection prior to drug administration, pathogen detection of biological military threats and a point-of-care for COVID-19 detection system for use in areas, such as healthcare, workplace screening, travel requirements, and confirmation of antigen tests. It serves medical, biotechnology, and pharmaceutical industries in the United Kingdom, Europe, the United States, and internationally. The company was formerly known as Epistem Holdings Plc and changed its name to genedrive plc in July 2016. The company was founded in 2000 and is headquartered in Manchester, the United Kingdom.